Oral bisphosphonates may greatly reduce the risk of endometrial cancer, according to a recent study published online ahead of print in the Journal of Clinical Oncology.

Polly Newcomb, PhD, MPH, of the Fred Hutchinson Cancer Research Center and colleagues conducted a large prospective cohort of 89,918 postmenopausal women who participated in the Women’s Health Initiative.

Continue Reading

RELATED: Soy, Isoflavone Intake Not Linked to Endometrial Cancer

“Several studies have found that use of bisphosphonates is associated with reduced risk of developing breast cancer, but less is known about associations with other common malignancies,” the authors noted.

Detailed interviews were conducted with patients at baseline, with bisphosphonate data at baseline and over follow-up. With a median follow-up of 12.5 years, 1,123 women were diagnosed with endometrial cancer.

They found that bisphosphonate use was associated with a reduced risk of endometrial cancer, with no interactions based on age, BMI, or indication for use.


  1. Newcomb, Polly A., et al. “Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer.” Journal of Clinical Oncology. doi: 10.1200/JCO.2014.58.6842. [epub ahead of print]. February 23, 2015.